We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Seizures following COVID‐19 vaccination in Mexico: A nationwide observational study.
- Authors
Núñez, Isaac; García‐Grimshaw, Miguel; Castillo Valencia, Carlos Yoel; Aguilera Callejas, Daniel Eduardo; Moya Alfaro, Mónica Libertad; Saniger‐Alba, María del Mar; Gutiérrez‐Romero, Alonso; Carrillo‐Mezo, Roger; Ceballos‐Liceaga, Santa Elizabeth; Baptista‐Rosas, Raúl C.; López‐Gatell, Hugo; Reyes‐Terán, Gustavo; Díaz‐Ortega, Jose Luis; Arauz, Antonio; Valdés‐Ferrer, Sergio Iván; Hernández‐Vanegas, Laura E.
- Abstract
The COVID‐19 pandemic led to the development and emergency approval of an array of effective vaccines against SARS‐CoV‐2. Given the relatively small number of patients included in vaccine trials, postapproval epidemiological surveillance is crucial to detect infrequent vaccine‐related adverse events. We conducted a nationwide retrospective descriptive study evaluating the incidence of seizures among recipients of SARS‐CoV‐2 vaccines in Mexico from December 24, 2020 (date of administration of first doses nationwide) to October 29, 2021. Among 81 916 351 doses of any vaccine that were administered, we documented seizures in 53 patients, of which 31 (60%) were new onset seizures. The incidence rate of seizures per million doses was highest for mRNA‐1273 (Moderna) with 2.73 per million, followed by BNT162b2 (Pfizer‐BioNTech) with 1.02 per million, and Ad5‐nCoV (CanSino) with 1.01 per million. Thus, we found that seizures following SARS‐CoV‐2 vaccination are exceedingly rare events.
- Subjects
MEXICO; COVID-19 vaccines; VACCINE trials; SEIZURES (Medicine); SCIENTIFIC observation; VACCINE effectiveness
- Publication
Epilepsia (Series 4), 2022, Vol 63, Issue 10, pe144
- ISSN
0013-9580
- Publication type
Article
- DOI
10.1111/epi.17390